Top 6 Tetanus Vaccines for UK Horses — Core Equine Vaccines 2026
Published on Thursday, 26 February 2026
Tetanus vaccination remains one of the most critical health measures for horses across the United Kingdom, protecting against Clostridium tetani — a bacterium that thrives in soil and can enter through minor wounds, particularly puncture injuries from farrier work or field hazards. British equestrian facilities, riding schools, and livery yards prioritise tetanus protection as a cornerstone of responsible horse management. This category within Equine Health First Aid > Equine Vaccines Immunization Supplies > Core Equine Vaccines focuses on tetanus prevention options available in the UK in 2026, covering single-antigen toxoid formulations and multivalent combination products that streamline vaccination protocols while maintaining robust tetanus immunity. UK owners and vets increasingly favour combination vaccines to reduce handling stress and the number of annual visits, especially for nervous horses and large yards managing multiple animals. When choosing a vaccine, buyers typically evaluate clinical efficacy, duration of immunity, cold-chain stability for reliable storage on yard or in remote locations, manufacturer support and availability in the UK, compatibility with existing vaccination schedules, and suitability for foals, pregnant mares and competition horses. Ease of administration, clear dosing guidance, and local veterinary endorsement also strongly influence purchasing decisions across the equestrian community from Scotland to the South West.
Top Picks Summary
Zoetis Equilis Tetanus Vaccine
Zoetis Equilis Tetanus Vaccine tops this 2025 UK list for its well-established safety profile and the company’s extensive distribution network that supports consistent supply across the United Kingdom. Compared with other entries, Equilis is positioned as a financially efficient choice for larger yards due to competitive multi-dose packaging and predictable shelf‑life, while maintaining comparable immunological performance to specialist formulations from Boehringer and MSD.
Boehringer Ingelheim Equilis Prequenza Te
Boehringer Ingelheim’s Equilis Prequenza Te is highlighted for its technical advantage as a combination-style product that reduces handling and clinic visits, which can lower overall administration costs despite a higher per-dose price. In the UK 2025 context it stands out versus single-antigen options by offering logistical savings for mixed-vaccine protocols, making it attractive to practices prioritising streamlined care over bare unit price.
What the Research Says about Tetanus Vaccination
A growing body of veterinary literature supports tetanus toxoid vaccination as the most effective prevention strategy against tetanus in horses. Research and clinical guidance emphasise timely primary vaccination, appropriate boosters, and practical storage and handling to preserve vaccine potency. Studies comparing single-antigen and combination products show that well-formulated multivalent vaccines can achieve comparable tetanus antibody responses while reducing the number of injections and associated stress for the animal. Evidence also highlights the importance of cold-chain management, clear priming and booster schedules, and consideration of maternal antibodies in foals when planning early-life vaccination.
High seroconversion rates: Several peer-reviewed studies report strong antibody responses to tetanus toxoid, with most vaccinated horses developing protective antibody levels within weeks of primary vaccination and booster doses sustaining immunity.
Combination vaccine efficacy: Comparative research in equine journals indicates that combination vaccines containing tetanus toxoid produce tetanus-specific immunity comparable to single-antigen formulations, while lowering handling frequency and logistical burden.
Duration of immunity: Clinical guidance and field studies support booster strategies that balance prolonged protection with practical yard management; many protocols recommend regular boosters tailored to vaccine type and risk exposure.
Maternal antibody considerations: Maternal antibodies can interfere with vaccine response in very young foals; veterinary guidance recommends scheduling primary vaccination to optimise immune response while protecting vulnerable foals.
Cold-chain importance: Stability studies and manufacturer data stress storage between 2 and 8 degrees Celsius and minimising freeze-thaw cycles to preserve potency during transport and on-yard storage.
Conclusion
This guide highlights leading tetanus vaccine options readily used across the UK: Zoetis Equilis Tetanus Vaccine, Boehringer Ingelheim Equilis Prequenza Te, MSD Animal Health Equip FT, Dechra Tetanus Antitoxin Behring, Boehringer Ingelheim Equilis Te, and Zoetis Duvaxyn IE-T Plus. Each product targets core tetanus protection needs, with single-antigen toxoids offering focused immunity and multivalent combinations simplifying yard workflows. For many UK owners managing mixed yards or nervous horses, a combination product such as Zoetis Duvaxyn IE-T Plus is often the best overall choice for balancing broad coverage with fewer handling events. We hope you found what you were looking for; if you want to refine results by vaccine type, foal or mare suitability, cold-chain requirements, or manufacturer support, use the search to expand or narrow your options.